Ionis Grants Recordati Rights to Zilganersen for Alexander Disease

Ionis grants Recordati rights to zilganersen for Alexander disease

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.The post Ionis grants Recordati rights to zilganersen for Alexander disease appeared first on Hospital Management.

Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy - European Biotechnology Magazine

Italian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease (AxD), in all countries outside the U.S. The post Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy appeared first on European Biotechnology Magazine.